Uae Cell Gene Therapy Manufacturing Market Report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030
Description
UAE Cell Gene Therapy Manufacturing
Market Overview
The UAE Cell Gene Therapy Manufacturing Market is valued at USD 30 million, based on a five-year historical analysis of country-level cell and gene therapy manufacturing revenues and related gene therapy activity in the UAE. This growth is primarily driven by advancements in biotechnology, increasing investments in healthcare infrastructure, and a rising prevalence of genetic disorders and cancers, particularly hematologic and rare inherited diseases. The market is also supported by a growing number of clinical trials, expanding regenerative medicine programs, and the establishment of specialized cell and gene therapy and GMP-capable facilities in the region, such as Abu Dhabi Stem Cells Center and collaborations for advanced therapies. Key players in this market include Dubai and Abu Dhabi, which dominate due to their robust healthcare systems, significant investments in research and development, and strategic partnerships with global biopharmaceutical companies. These cities are also home to advanced medical facilities and research institutions that foster innovation in cell and gene therapies, including centers such as Abu Dhabi Stem Cells Center, Cleveland Clinic Abu Dhabi, Burjeel Medical City, Dubai Healthcare City–based entities, and UAE University’s stem cell and regenerative medicine programs. In 2023, the UAE government implemented a regulatory framework aimed at enhancing the safety and efficacy of cell and gene therapies. This framework includes stringent guidelines for clinical trials and manufacturing processes, ensuring compliance with international standards. Key provisions are anchored in instruments such as the Cabinet Resolution No. 40 of 2016 on Regulating the Use of Biotechnology and its Products, issued by the UAE Cabinet, and subsequent implementing rules and health authority standards that cover approval pathways, quality and GMP requirements, traceability, and oversight of advanced therapies, supporting innovation while safeguarding patient health and safety.
UAE Cell Gene Therapy Manufacturing
Market Segmentation
By Therapy Type: The market is segmented into various therapy types, including CAR-T Cell Therapy, TCR-T Cell Therapy, Stem Cell Therapy, Gene Addition/Gene Augmentation Therapy, Gene Editing-based Therapy (e.g., CRISPR), and Others. By therapy class, cell therapies (including stem cell and CAR-T modalities) currently account for the largest share of manufacturing activity in the UAE, with cell therapy identified as the largest segment in country-level manufacturing revenues. Within advanced oncology-focused approaches, CAR-T Cell Therapy is emerging as a leading clinical subsegment in the wider Middle East, driven by its effectiveness in treating certain types of cancers, particularly hematological malignancies. The increasing number of global approvals for CAR-T therapies, their successful clinical outcomes, and early patient access and referral programs with multinational biopharma have supported growing interest and adoption in the UAE, while stem cell and other regenerative therapies remain central to locally developed programs. By Sponsor / Customer Type: The market is also segmented by sponsor or customer type, which includes Biopharmaceutical and Biotechnology Companies, Academic and Research Institutions, Hospitals and Specialty Clinics, Contract Development and Manufacturing Organizations (CDMOs), and Others. Biopharmaceutical and Biotechnology Companies dominate this segment due to their extensive resources and expertise in developing innovative therapies and their leading role in contracting specialized manufacturing services in cell and gene therapy globally and within the wider Middle East. Their strong focus on research and development, coupled with strategic collaborations with hospitals, research institutions, and technology providers, has positioned them as key drivers of pipeline expansion, technology transfer, and commercialization in the UAE cell and gene therapy landscape.
UAE Cell Gene Therapy Manufacturing Market
Competitive Landscape
The UAE Cell Gene Therapy Manufacturing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abu Dhabi Stem Cells Center (ADSSC), Dubai Stem Cell Center, Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi, Burjeel Medical City (Burjeel Holdings), Dubai Health (Dubai Academic Health Corporation), Mubadala Health / M42, G42 Healthcare (now M42), Dubai Healthcare City Authority, UAE University – Stem Cells and Regenerative Medicine Center, Novartis Pharma Services AG – UAE (Cell & Gene Therapy Division), Gilead Sciences / Kite Pharma – Middle East & UAE, NewBridge Pharmaceuticals FZ-LLC, Acrotech Biopharma / ACROBiosystems – GCC Presence, Pluristem Therapeutics Inc. – Abu Dhabi Collaboration contribute to innovation, geographic expansion, and service delivery in this space.
Abu Dhabi Stem Cells Center (ADSSC)
2019 Abu Dhabi, UAE
Dubai Stem Cell Center
2020 Dubai, UAE
Sheikh Shakhbout Medical City (SSMC)
2020 Abu Dhabi, UAE
Cleveland Clinic Abu Dhabi
2015 Abu Dhabi, UAE
Burjeel Medical City
2020 Abu Dhabi, UAE
Company
Establishment Year
Headquarters
Type of Player (Local Manufacturer, Global CDMO, Multinational Biopharma)
Installed GMP Manufacturing Capacity (Liters / Number of Suites)
Number of Cell & Gene Therapy Programs Supported (Preclinical + Clinical + Commercial)
UAE-derived Revenue from Cell & Gene Therapy Manufacturing
CAGR of Cell & Gene Manufacturing Revenue in UAE
Share of Autologous vs Allogeneic / Off-the-shelf Capacity
UAE Cell Gene Therapy Manufacturing Market Industry Analysis
Growth Drivers
Increasing Prevalence of Genetic Disorders: The UAE has witnessed a significant rise in genetic disorders, with approximately 1 in 4 Emiratis affected by genetic conditions. The World Health Organization reported that genetic disorders account for 20% of all childhood deaths in the region. This alarming statistic drives the demand for innovative therapies, including cell gene therapy, as healthcare providers seek effective solutions to address these challenges and improve patient outcomes. Advancements in Biotechnology: The UAE's biotechnology sector is rapidly evolving, with investments exceeding AED 1.5 billion in future. This growth is fueled by technological advancements in gene editing and cell therapy techniques, such as CRISPR and CAR-T. These innovations enhance the efficacy and safety of gene therapies, making them more accessible and appealing to healthcare providers and patients, thereby propelling market growth in the region. Rising Investment in R&D: The UAE government allocated AED 3 billion for research and development in the healthcare sector in future. This funding supports the development of cutting-edge gene therapies and encourages collaboration between private and public sectors. Increased R&D investment fosters innovation, leading to the creation of novel therapies that address unmet medical needs, thus driving the growth of the cell gene therapy manufacturing market.
Market Challenges
High Manufacturing Costs: The production of cell gene therapies involves complex processes and high-quality materials, leading to manufacturing costs that can exceed AED 1.2 million per treatment. These high costs pose a significant barrier to market entry for new players and limit the affordability of therapies for patients. As a result, many healthcare providers may hesitate to adopt these innovative treatments, hindering market growth. Regulatory Hurdles: The regulatory landscape for gene therapies in the UAE is still developing, with stringent approval processes that can delay product launches. For instance, the average time for clinical trial approvals can take up to 16 months. These regulatory challenges create uncertainty for manufacturers and may deter investment in the sector, ultimately impacting the availability of new therapies in the market.
UAE Cell Gene Therapy Manufacturing Market
Future Outlook
The future of the UAE cell gene therapy manufacturing market appears promising, driven by ongoing advancements in biotechnology and increasing healthcare investments. As the prevalence of genetic disorders continues to rise, the demand for innovative therapies will likely grow. Additionally, collaborations between research institutions and healthcare providers will foster the development of novel therapies, enhancing patient access and treatment options. The integration of artificial intelligence in manufacturing processes will further streamline operations, improving efficiency and reducing costs.
Market Opportunities
Expansion of Healthcare Infrastructure: The UAE is investing AED 4 billion in healthcare infrastructure in future, enhancing facilities and services. This expansion will create a conducive environment for the growth of cell gene therapy manufacturing, enabling better access to advanced treatments for patients and fostering innovation in the sector. Collaborations with Research Institutions: Partnerships between private companies and research institutions are on the rise, with over 20 collaborations established in future. These alliances facilitate knowledge sharing and resource pooling, accelerating the development of new therapies and enhancing the UAE's position as a leader in the cell gene therapy market.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
Market Overview
The UAE Cell Gene Therapy Manufacturing Market is valued at USD 30 million, based on a five-year historical analysis of country-level cell and gene therapy manufacturing revenues and related gene therapy activity in the UAE. This growth is primarily driven by advancements in biotechnology, increasing investments in healthcare infrastructure, and a rising prevalence of genetic disorders and cancers, particularly hematologic and rare inherited diseases. The market is also supported by a growing number of clinical trials, expanding regenerative medicine programs, and the establishment of specialized cell and gene therapy and GMP-capable facilities in the region, such as Abu Dhabi Stem Cells Center and collaborations for advanced therapies. Key players in this market include Dubai and Abu Dhabi, which dominate due to their robust healthcare systems, significant investments in research and development, and strategic partnerships with global biopharmaceutical companies. These cities are also home to advanced medical facilities and research institutions that foster innovation in cell and gene therapies, including centers such as Abu Dhabi Stem Cells Center, Cleveland Clinic Abu Dhabi, Burjeel Medical City, Dubai Healthcare City–based entities, and UAE University’s stem cell and regenerative medicine programs. In 2023, the UAE government implemented a regulatory framework aimed at enhancing the safety and efficacy of cell and gene therapies. This framework includes stringent guidelines for clinical trials and manufacturing processes, ensuring compliance with international standards. Key provisions are anchored in instruments such as the Cabinet Resolution No. 40 of 2016 on Regulating the Use of Biotechnology and its Products, issued by the UAE Cabinet, and subsequent implementing rules and health authority standards that cover approval pathways, quality and GMP requirements, traceability, and oversight of advanced therapies, supporting innovation while safeguarding patient health and safety.
UAE Cell Gene Therapy Manufacturing
Market Segmentation
By Therapy Type: The market is segmented into various therapy types, including CAR-T Cell Therapy, TCR-T Cell Therapy, Stem Cell Therapy, Gene Addition/Gene Augmentation Therapy, Gene Editing-based Therapy (e.g., CRISPR), and Others. By therapy class, cell therapies (including stem cell and CAR-T modalities) currently account for the largest share of manufacturing activity in the UAE, with cell therapy identified as the largest segment in country-level manufacturing revenues. Within advanced oncology-focused approaches, CAR-T Cell Therapy is emerging as a leading clinical subsegment in the wider Middle East, driven by its effectiveness in treating certain types of cancers, particularly hematological malignancies. The increasing number of global approvals for CAR-T therapies, their successful clinical outcomes, and early patient access and referral programs with multinational biopharma have supported growing interest and adoption in the UAE, while stem cell and other regenerative therapies remain central to locally developed programs. By Sponsor / Customer Type: The market is also segmented by sponsor or customer type, which includes Biopharmaceutical and Biotechnology Companies, Academic and Research Institutions, Hospitals and Specialty Clinics, Contract Development and Manufacturing Organizations (CDMOs), and Others. Biopharmaceutical and Biotechnology Companies dominate this segment due to their extensive resources and expertise in developing innovative therapies and their leading role in contracting specialized manufacturing services in cell and gene therapy globally and within the wider Middle East. Their strong focus on research and development, coupled with strategic collaborations with hospitals, research institutions, and technology providers, has positioned them as key drivers of pipeline expansion, technology transfer, and commercialization in the UAE cell and gene therapy landscape.
UAE Cell Gene Therapy Manufacturing Market
Competitive Landscape
The UAE Cell Gene Therapy Manufacturing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Abu Dhabi Stem Cells Center (ADSSC), Dubai Stem Cell Center, Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi, Burjeel Medical City (Burjeel Holdings), Dubai Health (Dubai Academic Health Corporation), Mubadala Health / M42, G42 Healthcare (now M42), Dubai Healthcare City Authority, UAE University – Stem Cells and Regenerative Medicine Center, Novartis Pharma Services AG – UAE (Cell & Gene Therapy Division), Gilead Sciences / Kite Pharma – Middle East & UAE, NewBridge Pharmaceuticals FZ-LLC, Acrotech Biopharma / ACROBiosystems – GCC Presence, Pluristem Therapeutics Inc. – Abu Dhabi Collaboration contribute to innovation, geographic expansion, and service delivery in this space.
Abu Dhabi Stem Cells Center (ADSSC)
2019 Abu Dhabi, UAE
Dubai Stem Cell Center
2020 Dubai, UAE
Sheikh Shakhbout Medical City (SSMC)
2020 Abu Dhabi, UAE
Cleveland Clinic Abu Dhabi
2015 Abu Dhabi, UAE
Burjeel Medical City
2020 Abu Dhabi, UAE
Company
Establishment Year
Headquarters
Type of Player (Local Manufacturer, Global CDMO, Multinational Biopharma)
Installed GMP Manufacturing Capacity (Liters / Number of Suites)
Number of Cell & Gene Therapy Programs Supported (Preclinical + Clinical + Commercial)
UAE-derived Revenue from Cell & Gene Therapy Manufacturing
CAGR of Cell & Gene Manufacturing Revenue in UAE
Share of Autologous vs Allogeneic / Off-the-shelf Capacity
UAE Cell Gene Therapy Manufacturing Market Industry Analysis
Growth Drivers
Increasing Prevalence of Genetic Disorders: The UAE has witnessed a significant rise in genetic disorders, with approximately 1 in 4 Emiratis affected by genetic conditions. The World Health Organization reported that genetic disorders account for 20% of all childhood deaths in the region. This alarming statistic drives the demand for innovative therapies, including cell gene therapy, as healthcare providers seek effective solutions to address these challenges and improve patient outcomes. Advancements in Biotechnology: The UAE's biotechnology sector is rapidly evolving, with investments exceeding AED 1.5 billion in future. This growth is fueled by technological advancements in gene editing and cell therapy techniques, such as CRISPR and CAR-T. These innovations enhance the efficacy and safety of gene therapies, making them more accessible and appealing to healthcare providers and patients, thereby propelling market growth in the region. Rising Investment in R&D: The UAE government allocated AED 3 billion for research and development in the healthcare sector in future. This funding supports the development of cutting-edge gene therapies and encourages collaboration between private and public sectors. Increased R&D investment fosters innovation, leading to the creation of novel therapies that address unmet medical needs, thus driving the growth of the cell gene therapy manufacturing market.
Market Challenges
High Manufacturing Costs: The production of cell gene therapies involves complex processes and high-quality materials, leading to manufacturing costs that can exceed AED 1.2 million per treatment. These high costs pose a significant barrier to market entry for new players and limit the affordability of therapies for patients. As a result, many healthcare providers may hesitate to adopt these innovative treatments, hindering market growth. Regulatory Hurdles: The regulatory landscape for gene therapies in the UAE is still developing, with stringent approval processes that can delay product launches. For instance, the average time for clinical trial approvals can take up to 16 months. These regulatory challenges create uncertainty for manufacturers and may deter investment in the sector, ultimately impacting the availability of new therapies in the market.
UAE Cell Gene Therapy Manufacturing Market
Future Outlook
The future of the UAE cell gene therapy manufacturing market appears promising, driven by ongoing advancements in biotechnology and increasing healthcare investments. As the prevalence of genetic disorders continues to rise, the demand for innovative therapies will likely grow. Additionally, collaborations between research institutions and healthcare providers will foster the development of novel therapies, enhancing patient access and treatment options. The integration of artificial intelligence in manufacturing processes will further streamline operations, improving efficiency and reducing costs.
Market Opportunities
Expansion of Healthcare Infrastructure: The UAE is investing AED 4 billion in healthcare infrastructure in future, enhancing facilities and services. This expansion will create a conducive environment for the growth of cell gene therapy manufacturing, enabling better access to advanced treatments for patients and fostering innovation in the sector. Collaborations with Research Institutions: Partnerships between private companies and research institutions are on the rise, with over 20 collaborations established in future. These alliances facilitate knowledge sharing and resource pooling, accelerating the development of new therapies and enhancing the UAE's position as a leader in the cell gene therapy market.
Please Note: The report will take approximately 4–6 weeks to prepare and deliver.
Update cycle typically involves:
Dataset refresh & triangulation from credible public sources + paid databases where applicable.
Competitive mapping (platform coverage, business model, revenue/traffic proxies where available, key vertical splits)
Validation pass to ensure numbers are directionally consistent (and avoid “stale” assumptions)
Finalizing the PDF + Excel with clear assumptions and definitions.
Table of Contents
98 Pages
- 1. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Overview
- 1.1. Definition and Scope
- 1.2. Market Taxonomy
- 1.3. Market Growth Rate
- 1.4. Market Segmentation Overview
- 2. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Size (in USD Bn), 2019–2024
- 2.1. Historical Market Size
- 2.2. Year-on-Year Growth Analysis
- 2.3. Key Market Developments and Milestones
- 3. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Analysis
- 3.1. Growth Drivers
- 3.1.1 Increasing prevalence of genetic disorders
- 3.1.2 Advancements in gene editing technologies
- 3.1.3 Rising investments in biotechnology
- 3.1.4 Supportive government initiatives for research
- 3.2. Restraints
- 3.2.1 High cost of gene therapy treatments
- 3.2.2 Regulatory challenges and approval processes
- 3.2.3 Limited awareness among healthcare providers
- 3.2.4 Ethical concerns surrounding gene manipulation
- 3.3. Opportunities
- 3.3.1 Expansion of personalized medicine
- 3.3.2 Collaborations between biotech firms and research institutions
- 3.3.3 Growth in regenerative medicine applications
- 3.3.4 Increasing demand for innovative therapies
- 3.4. Trends
- 3.4.1 Shift towards autologous cell therapies
- 3.4.2 Integration of artificial intelligence in gene therapy
- 3.4.3 Development of combination therapies
- 3.4.4 Focus on patient-centric treatment approaches
- 3.5. Government Regulation
- 3.5.1 Regulatory frameworks for gene therapy in the UAE
- 3.5.2 Guidelines for clinical trials and approvals
- 3.5.3 Compliance with international standards
- 3.5.4 Monitoring and post-market surveillance regulations
- 3.6. SWOT Analysis
- 3.7. Stakeholder Ecosystem
- 3.8. Competition Ecosystem
- 4. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Segmentation, 2024
- 4.1. By Therapy Type (in Value %)
- 4.1.1 Gene Editing
- 4.1.2 Gene Replacement
- 4.1.3 Gene Silencing
- 4.1.4 Others
- 4.2. By Application (in Value %)
- 4.2.1 Oncology
- 4.2.2 Rare Genetic Disorders
- 4.2.3 Cardiovascular Diseases
- 4.2.4 Others
- 4.3. By Patient Demographics (in Value %)
- 4.3.1 Pediatric
- 4.3.2 Adult
- 4.4. By Manufacturing Process (in Value %)
- 4.4.1 Viral Vector-Based
- 4.4.2 Non-Viral Vector-Based
- 4.4.3 Others
- 4.5. By Distribution Channel (in Value %)
- 4.5.1 Hospitals
- 4.5.2 Specialty Clinics
- 4.5.3 Research Institutions
- 4.5.4 Others
- 4.6. By Region (in Value %)
- 4.6.1 North India
- 4.6.2 South India
- 4.6.3 East India
- 4.6.4 West India
- 4.6.5 Central India
- 4.6.6 Northeast India
- 4.6.7 Union Territories
- 5. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Cross Comparison
- 5.1. Detailed Profiles of Major Companies
- 5.1.1 Novartis AG
- 5.1.2 Gilead Sciences, Inc.
- 5.1.3 Bluebird Bio, Inc.
- 5.1.4 Spark Therapeutics, Inc.
- 5.1.5 CRISPR Therapeutics AG
- 5.2. Cross Comparison Parameters
- 5.2.1 No. of Employees
- 5.2.2 Headquarters
- 5.2.3 Inception Year
- 5.2.4 Revenue
- 5.2.5 Production Capacity
- 6. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Regulatory Framework
- 6.1. Gene Therapy Standards
- 6.2. Compliance Requirements and Audits
- 6.3. Certification Processes
- 7. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Size (in USD Bn), 2025–2030
- 7.1. Future Market Size Projections
- 7.2. Key Factors Driving Future Market Growth
- 8. Uae Cell Gene Therapy Manufacturing Size, Share, Growth Drivers, Trends, Opportunities & – Market Future Segmentation, 2030
- 8.1. By Therapy Type (in Value %)
- 8.2. By Application (in Value %)
- 8.3. By Patient Demographics (in Value %)
- 8.4. By Manufacturing Process (in Value %)
- 8.5. By Distribution Channel (in Value %)
- 8.6. By Region (in Value %)
- Disclaimer
- Contact Us
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
